Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HRS-9821 in Healthy Volunteers and COPD Patients
NCT05622864Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-9821 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence and severity of adverse events at 1 month. Started Jan 2023; status: completed.
02
Drugs
HRS-9821
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05622864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622864.